Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-08-07
2007-08-07
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S143100, C424S155100, C424S181100, C435S007230, C435S069600, C435S070210, C530S387300, C530S388100, C530S388220, C530S388800, C530S391700
Reexamination Certificate
active
10603000
ABSTRACT:
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
REFERENCES:
patent: 4172124 (1979-10-01), Koprowski et al.
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchilin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 6657048 (2003-12-01), Young et al.
patent: 2002/0041877 (2002-04-01), Young et al.
patent: 2004/0001789 (2004-01-01), Young et al.
patent: WO95/20401 (1995-08-01), None
patent: WO02/082076 (2002-10-01), None
patent: WO03/055515 (2003-07-01), None
Campbell et al. Biology, 5th ed. p. 856, 1999.
Co et al. Nature, 351(6):501-502, Jun. 6, 1991.
D. Harris et al, “Serotherapy of cancer”, Seminars in Oncology, 16(3):180-198 (Jun. 1989).
H. Dvorak et al, “Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies”, Cancer Cells, 3(3):77-85 (Mar. 1991).
S. Engelholm et al, “Disaggregation of human solid tumours by combined mechanical and enzymatic methods”, Br. J. Cancer, 51:93-98 (1985).
A. Costa et al, “Implications of disaggregation procedures on biological representation of human solid tumours”, Cell Tisue Kinet., 20:171-180 (1987).
S. Dairkee et al, “Partial enzymatic degradation of stroma allows enrichment and expansion of primary breast tumor cells”, Cancer Research, 57:1590-1596 (Apr. 1997).
B. Franzen et al, “Nonenzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis”, Electrophoresis, 14:1045-1053 (1993).
E. Holz et al, “Antibody-based immunotherapeutic strategies in colorectal cancer”, Recent Results in Cancer Research, 142:381-400 (1996).
R. Dillman, “Antibodies as cytotoxic therapy”, J. Clin. Oncol., 12(7):1497-1515 (Jul. 1994).
R. Dillman, “Monoclonal antibodies for treating cancer”, Annals of Internal Medicine, 111:592-603 (1989).
M. Disis et al, “HER-2
eu protein: a target for antigen-specific immunotherapy of human cancer”, Advances in Cancer Research, 71:343-371 (1997).
A. Begg et al, “Rapid fluorescence-based assay for radiosensitivity and chemosensitivity testing in mammalian cells in vitro”, Cancer Research, 49:565-569 (Feb. 1989).
J. Cruse et al, Illustrated Dictionary of Immunology, CRC Press, p. 280 (1995).
A. Knuth et al, “ADCC reactivity of human melanoma cels with mouse monoclonal antibodies”, Proc. Am. Assoc. Cancer Res., 25:1005 (Mar. 1984) Abstract only.
J. Horoszewicz et al, “Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients”, Anticancer Research, 7:927-936 (1987).
D. Herlyn et al, “Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity”, Int. J. Cancer, 27:769-774 (1981).
V. Kravtsov et al, “Automated monitoring of apoptosis in suspension cell cultures”, Laboratory Investigation, 74(2):557-570 (1996).
L. Hartwell et al, “Integrating genetic approaches into the discovery of anticancer drugs”, Science, 278:1064-1068 (Nov. 1997).
B. Curti, “Physical barriers to drug delivery in tumors”, Critical Reviews in Oncology/Hematology, 14:29-39 (1993).
R. Jain, “Barriers to drug delivery in solid tumors”, Scientific American, 271(1):58-65 (Jul. 1994).
T. Gura, “Systems for identifying new drugs are often faulty”, Science, 278:1041-1042 (Nov. 1997).
G. Dermer, “Another anniversary for the war on cancer”, Bio/Technology, 12:320 (Mar. 1994).
R. Freshney, “Culture of animal cells”, a Manual of Basic Technique, Alan R. Liss, Inc., New York, p. 3 (1983).
T. Hsu, “Karyology of cells in culture—a preparation and analysis of karotypes and idiograms”, in Tissue Culture Methods and Applications, eds. Kruse and Patterson, Academic Press, New York, pp. 764-767 (1973).
M. Embleton, “Monoclonal antibodies to osteogenic sarcoma antigens”, Immunol. Ser., 23:181-207 (1984).
H. Drexler, “Recent results on the biology of Hodgkin and Reed-Stemberg cells”, Leukemia and Lymphoma, 9:1-25 (1993).
C. Badger et al, “Prospects for monoclonal antibody therapy of leukemia and lymphoma”, Cancer, 58:584-589 (1986).
E. Boven et al, “Monoclonal antibodies in cancer treatment: where do we stand after 10 years?”, Radiotherapy and Oncology, 5:109-117 (1986).
A. Epstein et al, “Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential”, Cancer Research, 47:830-840 (1987).
K. Foon, “Biological therapy of cancer”, Breast Cancer Research & Treatment, 7:5-14 (1986).
Findlay Helen P.
Hahn Susan E.
Takahashi Miyoko
Young David S. F.
Arius Research Inc.
Blanchard David J.
Huff Sheela J.
McHale & Slavin P.A.
LandOfFree
Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3862389